Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceralasertib plus Durvalumab vs Docetaxel in Advanced or Metastatic NSCLC (LATIFY)
NCT05450692Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2022
- Primary completion
- Oct 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 23
01
Overview
A Phase 3 trial of ceralasertib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Sep 2022; status: active, not recruiting.
02
Drugs
ceralasertib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05450692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05450692.